Literature DB >> 21823828

Lack of recurrence of imatinib-induced interstitial lung disease with nilotinib.

Thomas Delomas, Christian Darné, Caroline Besson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21823828     DOI: 10.3109/10428194.2011.606940

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  8 in total

Review 1.  Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2016-11       Impact factor: 5.606

2.  Imatinib-induced dose-dependent interstitial lung disease successfully switched to nilotinib: a case report with concentration exposure data.

Authors:  Kim Dao; Dana Védy; José Lopez; Olivier Staneczek; Thierry Buclin; Françoise Livio
Journal:  Int J Hematol       Date:  2012-12-28       Impact factor: 2.490

3.  Successful rechallenge with imatinib in a patient with chronic myeloid leukemia who previously experienced imatinib mesylate induced pneumonitis.

Authors:  Seong Woo Go; Boo Kyeong Kim; Sung Hak Lee; Tae-Jung Kim; Joo Yeon Huh; Jong Min Lee; Jick Hwan Hah; Dong Whi Kim; Min Jung Cho; Tae Wan Kim; Ji Young Kang
Journal:  Tuberc Respir Dis (Seoul)       Date:  2013-12-24

4.  Imatinib-Induced Interstitial Pneumonitis Successfully Switched to Nilotinib in a Patient with Prior History of Mycobacterium tuberculosis Infection.

Authors:  Zhuan Bo Luo; Ning Xu; Xiao Ping Huang; Gui Fang Ouyang
Journal:  Turk J Haematol       Date:  2017-07-28       Impact factor: 1.831

5.  Imatinib-induced irreversible interstitial lung disease: A case report.

Authors:  Ping Zhang; Jingfeng Huang; Fangfang Jin; Jiaohai Pan; Guifang Ouyang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

6.  A case report of nilotinib-induced irreversible interstitial lung disease.

Authors:  Jun Yeun Cho; Ok-Jun Lee; Jihyun Kwon; Dohun Kim; Yoon Mi Shin
Journal:  Medicine (Baltimore)       Date:  2022-01-28       Impact factor: 1.889

7.  Nilotinib-induced interstitial lung disease.

Authors:  Se-Il Go; Won Sup Lee; Gyeong-Won Lee; Jung Hun Kang; Myung Hee Kang; Jeong-Hee Lee; Hoon-Gu Kim
Journal:  Int J Hematol       Date:  2013-07-23       Impact factor: 2.490

8.  Dasatinib-induced Nonspecific Interstitial Pneumonia That Developed 7 Years after the Initiation of Dasatinib.

Authors:  Daisuke Takekoshi; Yuma Matsui; Takuya Akutsu; Ayako Nishioka; Ayu Kiritani; Keitaro Okuda; Junko Watanabe; Hanae Miyagawa; Hirohumi Utsumi; Mitsuo Hashimoto; Hiroshi Wakui; Shunsuke Minagawa; Hiromichi Hara; Takanori Numata; Yuki Noda; Rei Makishima; Masahiro Ikegami; Yoshinori Kawabata; Jun Araya; Kazuyoshi Kuwano
Journal:  Intern Med       Date:  2020-06-15       Impact factor: 1.271

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.